These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

644 related articles for article (PubMed ID: 6335397)

  • 21. Similarities in function between pancreatic tumor cells and macrophages and their inhibition by murine monoclonal antibodies.
    Schorlemmer HU; Bosslet K; Kern HF; Sedlacek HH
    Behring Inst Mitt; 1988 Apr; (82):240-64. PubMed ID: 3408453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody-independent activation of C1. I. Differences in the mechanism of C1 activation by nonimmune activators and by immune complexes: C1r-independent activation of C1s by cardiolipin vesicles.
    Kovacsovics TJ; Peitsch MC; Kress A; Isliker H
    J Immunol; 1987 Mar; 138(6):1864-70. PubMed ID: 3029222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The functions of endogenous C1q, a subcomponent of the first component of complement, as a receptor on the membrane of macrophages.
    Loos M
    Mol Immunol; 1982 Oct; 19(10):1229-38. PubMed ID: 6184611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody-independent C1 activation by E. coli.
    Tenner AJ; Ziccardi RJ; Cooper NR
    J Immunol; 1984 Aug; 133(2):886-91. PubMed ID: 6376630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.
    Fan Z; Masui H; Altas I; Mendelsohn J
    Cancer Res; 1993 Sep; 53(18):4322-8. PubMed ID: 8364927
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conformational changes in C1q after binding to immune complexes: detection of neoantigens with monoclonal antibodies.
    Golan MD; Burger R; Loos M
    J Immunol; 1982 Aug; 129(2):445-7. PubMed ID: 6177765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exogenous C1q reconstitutes resident but not inflammatory mouse peritoneal macrophages for Fc receptor-dependent cellular cytotoxicity and phagocytosis. Relationship to endogenous C1q availability.
    Leu RW; Zhou AQ; Rummage JA; Kennedy MJ; Shannon BJ
    J Immunol; 1989 Nov; 143(10):3250-7. PubMed ID: 2809201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of a human granulocyte functional antigen (GFA-2) involved in antibody-dependent cell-mediated cytotoxicity and phagocytosis.
    López AF; Begley G; Andrews P; Butterworth AE; Vadas MA
    J Immunol; 1985 Jun; 134(6):3969-77. PubMed ID: 3989303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Secreted chondroitin sulfate proteoglycan of human B cell lines binds to the complement protein C1q and inhibits complex formation of C1.
    Kirschfink M; Blase L; Engelmann S; Schwartz-Albiez R
    J Immunol; 1997 Feb; 158(3):1324-31. PubMed ID: 9013976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The binding site for C1q on IgG.
    Duncan AR; Winter G
    Nature; 1988 Apr; 332(6166):738-40. PubMed ID: 3258649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Production and characterization of a murine monoclonal IgM antibody to human C1q receptor (C1qR).
    Ghebrehiwet B
    J Immunol; 1986 Jul; 137(2):618-24. PubMed ID: 3487576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. C1q acts synergistically with phorbol dibutyrate to activate CR1-mediated phagocytosis by human mononuclear phagocytes.
    Bobak DA; Frank MM; Tenner AJ
    Eur J Immunol; 1988 Dec; 18(12):2001-7. PubMed ID: 2975599
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Possible mechanisms of the first step of the classical complement activation pathway: binding and activation of C1.
    Füst G; Medgyesi GA; Rajnavölgyi E; Csécsi-Nagy M; Czikora K; Gergely J
    Immunology; 1978 Dec; 35(6):873-84. PubMed ID: 104923
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stimulation of human neutrophil Fc receptor-mediated phagocytosis by a low molecular weight cytokine.
    Gresham HD; Clement LT; Lehmeyer JE; Griffin FM; Volanakis JE
    J Immunol; 1986 Aug; 137(3):868-75. PubMed ID: 3522738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The distortive mechanism for the activation of complement component C1 supported by studies with a monoclonal antibody against the "arms" of C1q.
    Hoekzema R; Martens M; Brouwer MC; Hack CE
    Mol Immunol; 1988 May; 25(5):485-94. PubMed ID: 3261834
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Surface-bound capsular polysaccharide of type Ia group B Streptococcus mediates C1 binding and activation of the classic complement pathway.
    Levy NJ; Kasper DL
    J Immunol; 1986 Jun; 136(11):4157-62. PubMed ID: 3517165
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of immune precipitation by purified classical pathway complement components.
    Naama JK; Hamilton AO; Yeung-Laiwah AC; Whaley K
    Clin Exp Immunol; 1984 Nov; 58(2):486-92. PubMed ID: 6333948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Leukocyte-derived complement inhibitor. IV. The functional properties of C1 bound to erythrocytes pretreated with leukocyte culture supernatant.
    Bernard A; Walter W; Teshima H; Boumsell L; Good RA; Day NK
    J Immunol; 1976 Oct; 117(4):1117-26. PubMed ID: 977945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Purification and characterization of the 1q subcomponent of canine complement and its use in the 125I-C1q binding assay for detection of immune complexes.
    Wu CC; Bey RF; Loken KI
    Am J Vet Res; 1988 Jun; 49(6):865-9. PubMed ID: 3135770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. C1q binding and C1 activation by various isolated cellular membranes.
    Storrs SB; Kolb WP; Olson MS
    J Immunol; 1983 Jul; 131(1):416-22. PubMed ID: 6602834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.